A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 613 participants.

Also called NCT04492722

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 613 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
  • Parexel Registry lists this organization as a collaborator
Registry
  • NCT NCT04492722
  • EudraCT 2020-002263-54
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, Germany, Hungary, Israel, Japan, Malaysia, Poland, Taiwan, Ukraine (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT04492722. Randomized; quadruple masking; primary purpose treatment. Start 2020-10-01 (actual); primary completion 2022-09-06 (actual). Results posted on 2023-12-26.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
Intervention (Drug)
AZD5718
Intervention (Drug)
Dapagliflozin 10 mg
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)
Collaborator
Parexel (class: industry)
Collaborator
Emerald Clinical Inc. (class: industry)

Record details

Record id
cardio:ct-nct04492722
Content hash
3182bcb2d3ddf0106b4a22071d6094122fcda2b399c8222129d15c57173c58a8